Palliative care for patients with irresectable or recurrent cancer of the upper gastrointestinal tract: a randomized study
Completed
- Conditions
- Esophageal, pancreatic or hepatobiliairy cancerCancerOesophageal cancer, pancreatic cancer, hepatobiliairy cancer
- Registration Number
- ISRCTN86515732
- Lead Sponsor
- Health Care Research Program Erasmus MC 2003 (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
1. Patients with irresectabel or recurrent esophageal cancer, pancreatic cancer or hepatobiliary cancer, for whom no curative treatment options are available
2. Informed consent
Exclusion Criteria
1. Not able to understand or read the Dutch language
2. Undergoing treatment with chemotherapy or radiotherapy or a combination
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life questionnaires
- Secondary Outcome Measures
Name Time Method Patient satisfaction (questionnaire) costs
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of palliative care in ISRCTN86515732 for upper gastrointestinal cancer?
How does palliative care in ISRCTN86515732 compare to standard-of-care for recurrent esophageal and pancreatic cancer?
What biomarkers correlate with improved outcomes in palliative care for hepatobiliary cancer patients in ISRCTN86515732?
What adverse events are associated with palliative care interventions in upper gastrointestinal cancer trials?
Are there combination therapies or targeted agents that enhance palliative care efficacy in ISRCTN86515732's patient population?